Market Cap 23.45M
Revenue (ttm) 15.65M
Net Income (ttm) -370,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2.36%
Debt to Equity Ratio 0.00
Volume 46,100
Avg Vol 53,902
Day's Range N/A - N/A
Shares Out 5.39M
Stochastic %K 82%
Beta 0.52
Analysts Sell
Price Target $9.77

Company Profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 439 5551
Address:
100 Summit Drive, Burlington, United States
joe77w
joe77w Feb. 22 at 1:16 PM
$NEUP most recent 10Q said It all imo: https://www.otcmarkets.com/filing/html?id=19154438&guid=bJ3-kWNUzP-8ooh Glty
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 2:08 AM
$NEUP Current Stock Price: $4.41
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 18 at 2:44 PM
$NEUP has good cash runway + assets + MSD partnership. Maybe the next$SNSE ?
0 · Reply
d_risk
d_risk Feb. 17 at 11:24 PM
$NEUP - Neuphoria Therapeutics Inc. - 10Q - Updated Risk Factors NEUP’s 10-Q risk update pivots from drug development to an active strategic alternatives process post–Phase 3 failure, flagging costly and uncertain M&A or dissolution, potential asset devaluation, leadership and workforce disruption, contract/consent hurdles, expanded litigation exposure, and heightened risk that any deal—or lack thereof—may erode shareholder value. #Biotechnology #StrategicAlternatives #MergersAndAcquisitions #LitigationRisk #ShareholderValue 🟢 Added 🟠 Removed https://d-risk.ai/NEUP/10-Q/2026-02-17
0 · Reply
guidoschini
guidoschini Feb. 9 at 9:00 PM
$NEUP NEUP will not give more earnings or satisfaction
0 · Reply
SurgeShares
SurgeShares Feb. 9 at 3:26 PM
$NEUP Neuropathy or neurology biotech; CNS development is high-risk.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 5:28 PM
$NEUP RSI: 37.11, MACD: -0.0515 Vol: 0.07, MA20: 4.07, MA50: 4.07 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Quido22
Quido22 Feb. 4 at 5:10 PM
$NEUP If a deal is only verbally agreed (price, handshake, board alignment) and nothing is signed, there is no SEC filing obligation yet. The 8-K requirement is triggered only after a definitive merger agreement is executed. Reaching that point typically takes 2–6 weeks of intensive legal work: drafting the merger agreement, due diligence, negotiating reps and warranties, termination provisions, financing terms, closing conditions, and obtaining formal board approvals. Once the agreement is signed, the company must file an 8-K within 4 business days (often sooner). So a verbal deal on January 8 would normally lead to a first 8-K in late January to mid-February. If it appears much later, it usually signals delays, renegotiation, or a deal that wasn’t finalized—not mere administrative slowness.
0 · Reply
frontiere
frontiere Jan. 28 at 9:43 PM
$NEUP Neuphoria ex $BNOX Bionomics 👇 and to be clear, any deal takes time to draft negotiate structure review etc, I’ve worked on them and it can take weeks to months if thorough enough and esp if shopped around. So no clue if we are talking here days or months till some finale. But think highly likely some deal will come. Just that the timing and price levels will make a big difference for us, longs
0 · Reply
frontiere
frontiere Jan. 28 at 6:30 PM
$BNOX $NEUP Bionomics Neuphoria - on 9 Jan CEO moves to consulting setup with change of control earnouts if within 12 months - and afterwards still crickets. No Lynx1 news…
1 · Reply
Latest News on NEUP
Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Nov 24, 2025, 8:00 AM EST - 3 months ago

Neuphoria Therapeutics Inc. Sends Letter to Stockholders


Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025, 4:22 PM EDT - 9 months ago

Neuphoria Provides First Quarter 2025 Business Updates


Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Apr 15, 2025, 8:00 AM EDT - 11 months ago

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans


joe77w
joe77w Feb. 22 at 1:16 PM
$NEUP most recent 10Q said It all imo: https://www.otcmarkets.com/filing/html?id=19154438&guid=bJ3-kWNUzP-8ooh Glty
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 2:08 AM
$NEUP Current Stock Price: $4.41
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 18 at 2:44 PM
$NEUP has good cash runway + assets + MSD partnership. Maybe the next$SNSE ?
0 · Reply
d_risk
d_risk Feb. 17 at 11:24 PM
$NEUP - Neuphoria Therapeutics Inc. - 10Q - Updated Risk Factors NEUP’s 10-Q risk update pivots from drug development to an active strategic alternatives process post–Phase 3 failure, flagging costly and uncertain M&A or dissolution, potential asset devaluation, leadership and workforce disruption, contract/consent hurdles, expanded litigation exposure, and heightened risk that any deal—or lack thereof—may erode shareholder value. #Biotechnology #StrategicAlternatives #MergersAndAcquisitions #LitigationRisk #ShareholderValue 🟢 Added 🟠 Removed https://d-risk.ai/NEUP/10-Q/2026-02-17
0 · Reply
guidoschini
guidoschini Feb. 9 at 9:00 PM
$NEUP NEUP will not give more earnings or satisfaction
0 · Reply
SurgeShares
SurgeShares Feb. 9 at 3:26 PM
$NEUP Neuropathy or neurology biotech; CNS development is high-risk.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 5:28 PM
$NEUP RSI: 37.11, MACD: -0.0515 Vol: 0.07, MA20: 4.07, MA50: 4.07 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Quido22
Quido22 Feb. 4 at 5:10 PM
$NEUP If a deal is only verbally agreed (price, handshake, board alignment) and nothing is signed, there is no SEC filing obligation yet. The 8-K requirement is triggered only after a definitive merger agreement is executed. Reaching that point typically takes 2–6 weeks of intensive legal work: drafting the merger agreement, due diligence, negotiating reps and warranties, termination provisions, financing terms, closing conditions, and obtaining formal board approvals. Once the agreement is signed, the company must file an 8-K within 4 business days (often sooner). So a verbal deal on January 8 would normally lead to a first 8-K in late January to mid-February. If it appears much later, it usually signals delays, renegotiation, or a deal that wasn’t finalized—not mere administrative slowness.
0 · Reply
frontiere
frontiere Jan. 28 at 9:43 PM
$NEUP Neuphoria ex $BNOX Bionomics 👇 and to be clear, any deal takes time to draft negotiate structure review etc, I’ve worked on them and it can take weeks to months if thorough enough and esp if shopped around. So no clue if we are talking here days or months till some finale. But think highly likely some deal will come. Just that the timing and price levels will make a big difference for us, longs
0 · Reply
frontiere
frontiere Jan. 28 at 6:30 PM
$BNOX $NEUP Bionomics Neuphoria - on 9 Jan CEO moves to consulting setup with change of control earnouts if within 12 months - and afterwards still crickets. No Lynx1 news…
1 · Reply
Quido22
Quido22 Jan. 21 at 9:59 PM
$NEUP This is being bought out probably, check the SECs
1 · Reply
Quido22
Quido22 Jan. 20 at 4:19 PM
$NEUP I searched the board members linkedin, they all state there they stopped working in neuphoria at 31.12. all have new jobs. What is going on? what are your toughts? Why is in spyros resignment the sentence "strategic transaction"? Is this stock sold? merged? Or what else? Why no sec filling?
0 · Reply
I_am_retail_investor
I_am_retail_investor Jan. 16 at 8:33 PM
$NEUP - when will we see a NewUP for this stock?
1 · Reply
I_am_retail_investor
I_am_retail_investor Jan. 9 at 10:48 PM
$NEUP - JPMorgan Healthcare next week, great period for $NEUP to make a positive announcement
0 · Reply
I_am_retail_investor
I_am_retail_investor Jan. 9 at 5:07 PM
$NEUP - feels like something is happening via the chart .. anyone’s magic eight ball guess!
1 · Reply
Quido22
Quido22 Jan. 8 at 2:10 PM
$NEUP BUYOUT OR MERGER INCOMING. Mr. Papapetropoulos will serve as the interim CEO to the Company for up to twelve months to support the execution of the Company’s contemplated strategic transaction and ensure a seamless transition"
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Jan. 8 at 1:29 PM
$NEUP I Wasn't Expecting This, CEO Resigned ❓ Buyout Coming ❓ https://ir.neuphoriatx.com/node/11436/html
0 · Reply
stabbed
stabbed Jan. 7 at 8:04 PM
$NEUP - back in! Let's Go!
0 · Reply
Redposition
Redposition Jan. 7 at 6:50 PM
$NEUP Why down 🤔
0 · Reply
Quido22
Quido22 Jan. 6 at 2:44 PM
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Jan. 5 at 9:47 PM
$NEUP https://clinicaltrials.gov/study/NCT06721156?tab=history&a=33#version-content-panel
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Jan. 5 at 9:37 PM
$NEUP https://www.merck.com/news/merck-showcases-data-for-alzheimers-disease-candidates-mk-2214-and-mk-1167-at-ctad-2025/
1 · Reply